United States: Silicon Valley Venture Survey - Fourth Quarter 2014

Background

We analyzed the terms of 150 venture financings closed in the fourth quarter of 2014 by companies headquartered in Silicon Valley.

Overview of Fenwick & West Results

Valuation results continued very strong in 4Q14.

  • Up rounds exceeded down rounds 79% to 6%, with 15% flat. This was an increase from 3Q14 when up rounds exceeded down rounds 76% to 12%, with 12% flat.
  • The Fenwick & West Venture Capital Barometer" showed an average price increase in 4Q14 of 115%, an increase over the 79% recorded in 3Q14, and the highest amount recorded since we began calculating this statistic in 2005.
  • The median price increase of financings in 4Q14 was 61%, an increase from the 43% registered in 3Q14.
  • The software industry again led all industries with 50% of the deals and the highest median price increase, while internet/digital media had the second largest percentage of deals and the highest average price increase and highest percentage of up rounds. The hardware industry also had very good returns and the life science industry had solid returns.
  • We note that the valuation strength was seen across series, and that investor favorable terms such as senior liquidation preference were used relatively infrequently.

Overview of Other Industry Data

The U.S. venture ecosystem in general had a very strong 4Q14 and full year 2014. Venture investments (in dollars), the number of venture backed IPOs and proceeds from the acquisition of venture backed companies all hit their highest annual levels since 2000. That said, there are some aspects that bear noting.

  • Venture investment (in dollars) in 4Q14 and full year 2014 hit its highest levels since 2000. But the number of deals was basically flat for both time periods, indicating that the increased investment is going into larger rounds, not more companies. Many of those large rounds are late stage rounds that might have been public fundings in previous economic cycles when companies went public earlier.
  • The number of venture backed IPOs increased slightly in 4Q14, and significantly for the full year 2014, which had the highest number of IPOs since 2000. However, most of the IPOs for both periods were life science companies, and in January 2015 seven of the eight venture backed IPOs were in the life sciences industry.
  • Venture valuations continued to increase, but the public market was not as frothy.
  • M&A provided substantial proceeds in both 4Q14 and full year 2014, with 2014 proceeds the highest since 2000. But the number of deals declined in 4Q14 and was up only modestly for the full year.
  • The amount raised by venture funds declined in 4Q14, but increased significantly for the full year, hitting its highest level since 2007. The number of funds raising money increased noticeably for the quarter and the year, with 2014 having the largest number of funds raising money since 2001. The top 3% of funds raised over one-third of the money.
  • The percentage of U.S. venture investment coming from corporate VCs in 2014 reached its highest level since 2001. However, the percentage declined each quarter of 2014.
  • The crowdfunding sector is continuing to grow and innovate, and its effect on the venture ecosystem and potential for disruption appears to be increasing.
  • Conclusion: The companies that are at the lead in creating significant new industries or disrupting old industries are receiving huge venture investments at very high valuations, but the exuberance is selective. Compared to the dot-com years, far fewer companies are being funded or going public, venture funds are raising less money, and the public markets are much more discerning.

Venture Capital Investment

Venture capital investment in U.S. companies (in dollar terms) increased significantly in both 4Q14 and for the full year of 2014. However, the number of venture deals was effectively flat for both the quarter and the year, as deal size increased. A summary of the results published by three leading providers of venture data is below.

3Q14 Investing into Venture Backed U.S. Companies

4Q14
($Billions)
3Q141
($Billions)
Difference
%
4Q14
Deals
3Q141
Deals
Difference
%
VentureSource2 $13.8 $11.0 25% 814 899 -9.5%
MoneyTree3 $14.8 $9.9 49% 1,109 1,023 8.4%
CBI4 $13.5 $9.8 38% 884 878 0%
Average $14.0 $10.2 37% 936 933 0%

1. As reported April 2014
2. Dow Jones VentureSource ("VentureSource")
3. The PWC/NVCA MoneyTree" Report based on data from Thomson Reuters ("MoneyTree")
4. CB Insights ("CBI")

Full Year 2014 Investing into Venture Backed U.S. Companies

2014
($Billions)
2013
($Billions)
Difference
%
2014
Deals
2013
Deals
Difference
%
VentureSource $52 $35 47% 3,682 3,837 -4%
MoneyTree $48 $30 61% 4,356 4,193 4%
CBI $47 $29 62% 3,617 3,354 8%
Average $49 $31 58% 3,885 3,795 2%

As indicated in the chart below, investment levels in 4Q14 were the highest since the "dot-com bubble" years of 1999-2000. Note, however, that the amounts in the chart are not inflation adjusted, and that the current trend of companies staying private longer has likely resulted in more later stage venture financings than would have been seen in the past, when companies went public quicker and obtained later stage financing from the public markets.

Software companies received 41% of total venture investment in 2014, the highest percentage since at least 1995, with internet specific companies receiving 25% and life science companies receiving 18%, according to the MoneyTree. There were over 40 deals in 2014 that raised over $100 million.

IPO Activity

There were 21 venture backed U.S. IPOs raising $3 billion in 4Q14, basically flat with the 22 IPOs in 3Q14, but a significant increase from the $1.3 billion raised in 3Q14, according to VentureSource. For the full year 2014 there were 105 venture back IPOs raising $9.2 billion, a 42% and 12% increase respectively from the 74 IPOs raising $8.2 billion in 2013.

Similarly Thomson Reuters and the NVCA ("Thomson/NVCA") reported an 18% increase in the number of IPOs and a 68% increase in the amount raised in 4Q14 compared to 3Q14, and a 42% increase in IPOs and a 39% increase in the amount raised in 2014 compared to 2013.

Tech IPOs Mixed, Life Science Strong

For the second year in a row, biotech companies accounted for a majority of the IPOs in 2014, totaling 59 deals, the sector's largest number of IPOs since at least 1994. Life science companies in general accounted for 70% of 2014 venture backed IPOs and 60% (16) of 4Q14 IPOs. However tech companies, with only ten 4Q14 IPOs, raised $2.4 billion, compared to $1.7 billion for the 16 life science companies.

The public markets generally do not appear to be deferring to venture capital valuations in pricing IPOs, nor providing public tech companies with exuberant valuations. For example, the recent New Relic, Hortonworks and Box IPOs all priced below their most recent venture round price, and large tech companies like Google, Apple, Microsoft and IBM were all trading at forward P/Es below the average of the S&P 500, per Yahoo Finance. The Thomson Post-Venture Capital Index, which measures the change in stock price of venture backed companies that went public over the past ten years, was down 15% in 2014, compared to Nasdaq which was up 13%.

Merger and Acquisition Activity

There were 102 acquisitions of venture backed companies for a total of $32.3 billion in 4Q14, a 60% increase in dollar volume but a 23% decline in deal volume from 3Q14 (as reported in October 20141), according to VentureSource. If the $19 billion WhatsApp acquisition, which closed in 4Q14, was excluded, the dollar volume of 4Q14 M&A would have declined 34% from 3Q14.

For the full year of 2014 there were 531 acquisitions for $85 billion, an 18% and 107% increase respectively over the 449 acquisitions and $41 billion raised in 2013 (the dollar increase would have been 61% without WhatsApp). The amount of acquisition proceeds was the highest since 2000 by a large amount.

Similarly, Thomson/NVCA reported 95 acquisitions in 4Q14, a 20% decrease from 3Q14, and 445 acquisitions in all of 2014, a 16% increase over 2013.

Venture Capital Fundraising

U.S. venture funds raised $5.6 billion in 75 funds in 4Q14, an 8% decline in dollars and a 25% increase in funds compared to the $6.1 billion raised by 60 funds in 3Q14 (as reported in October 20141), according to Thomson/NVCA. For the entire year, $30 billion was raised by 254 funds, a 69% increase in dollars and a 23% increase in number of funds from the $17.7 billion raised by 207 funds in 2013. However, fundraising dollars declined in every quarter of 2014 (Q1 - $10B, Q2 - $8B, Q3 - $6.2B, Q4 - $5.6B).

Similarly, VentureSource reported $33 billion raised by 332 funds in 2014, a 62% increase in dollars and a 27% increase in funds over 2013.

Fundraising is following a barbell pattern, with approximately 100 of the funds closed in 2014 being less than $50M, a 180% increase over 2013, according to CBI, and with eight $1 billion or larger funds accounting for over one third of the total funds raised during the year, according to VentureWire.

Note that amounts reported to be raised by U.S. venture funds do not include amounts raised by other types of investment entities, such as corporate venture, mutual and hedge funds, sovereign wealth funds, non-U.S. venture firms and seed funds, which also invest to varying degrees in venture backed companies.

Global Venture Investing

Global venture investing has been increasing, with the U.S. receiving by far the largest amount of total investment, although that percentage has been declining modestly in recent years to about 64% in 2014. China surpassed Europe in 2014 for second place, with India ascending. It will be interesting to see what effect, if any, the new draft Foreign Investment Law released by the Chinese Ministry of Commerce will have on venture investment in China.

Corporate Venture Investing

Corporate venture capital ("CVC") groups invested more money in 2014 ($5.4 billion) than in any year since 2000 (which had a huge $15 billion investment), and was a larger percentage of total VC investment (11%) than in any year since 2001 (11.2%) according to the MoneyTree. However, the percentage of CVC investment declined each quarter of 2014, with 4Q14 at 9.8%.

The life science industry had its highest percent of CVC (13%) and total dollar investment ($1.1 billion) since at least 1995.

Over the past five years, the number of corporate venture units worldwide has doubled to 1100, and 25 of the 30 companies that comprise the Dow Jones have a venture fund, according to the Economist based on data from Global Corporate Venturing.

Accelerators

As the accelerator industry grows, it is challenging but important to have good information on the industry to evaluate the success of the industry in general, and specific accelerators in particular.

At the big picture level, Seed-DB reports that they are tracking 225 accelerators worldwide, and that these accelerators have assisted 4264 companies which have gone on to raise a total of $7.2 billion and returned $3.3 billion in 243 exits. Of course many of these accelerators and companies are relatively young and have not had much chance to raise significant funds, much less exit. It will be interesting to follow the results over time.

More detailed information is available about Techstars, which is one of the largest and most transparent accelerators. The Wall Street Journal reports, based on analysis from the Venture Capital Dispatch, that for companies that went through the Techstar program from 2007-2010 (which would give the companies a reasonable amount of time to mature), 37% are still active, 33% have failed and 30% were acquired.

The Seed Accelerator Ranking Project is working to evaluate the success and rank individual accelerators, but to date limited information is available.

The task of comparing accelerators may become harder as accelerators evolve and differentiate. Techstars, for example, is offering a new program that focuses more on later stage companies, and another program that has stronger corporate involvement and allows start-ups to embed themselves for part of the program in companies like Disney, Qualcomm, the Mayo Clinic, Barclays and Sprint, according to Fortune.

Crowdfunding

AngelList reported that over $100 million was raised by 243 start ups in 2014, with 110 active syndicates. And AngelList continues to innovate, as Fortune reports that it is considering a financial ETF type product targeting institutional investors who are interested in seed investing but have not had the opportunity to date to do so, because of the lack of scale and size of prior seed investment opportunities.

AngelList and crowdfunding in general pose an interesting challenge for venture capitalists, as they appear to be developing as a potential competitor, as well as a source of deal flow.

Crowdfunding is also growing outside the U.S., where start-up funding may be less available. The World Bank estimates that the global crowdfunding market is projected to reach $93 billion by 2025, with a significant percentage in China.

This past year concluded without the SEC adopting rules allowing equity crowdfunding sites to accept participation from non-accredited investors. This is an area where balancing investor protection and investment efficiency is difficult, and according to Crowdfund Insider, Congress may choose to step in to provide further guidance to the SEC.

Miscellaneous

As the college football season has ended, we thought we'd share Pitchbook's analysis of how the major football conferences (and the Ivy league) have compared, based on the number of venture deals closed by CEOs who are alums of each conferences' undergraduate program.

In short, the Pac 12 led, followed by the Ivy League, Big Ten, ACC, Big 12 and SEC, by number of financings. The Ivies and Big Ten, and SEC and Big 12, would have flipped position if based on dollar volume. The Pac 12, Ivies, Big Ten and ACC all had SaaS as their largest industry focus while the Big 12's largest industry was life science and the SEC's largest industry was mobile.

Venture Capital Sentiment

The Silicon Valley Venture Capitalist Confidence Index by Professor Mark Cannice at the University of San Francisco (the "Cannice Report") reported that the confidence level of Silicon Valley venture capitalists in 4Q14 was 3.93, a slight increase from the 3.89 posted in 3Q14 and above the 11-year survey average of 3.72. Venture capitalists noted the strong exit, investment and fundraising environments, and the breadth of innovation and entrepreneurial opportunities, but expressed concern over valuations and possible macroeconomic risks.

Venture Capital Returns

Cambridge Associates reported that the value of its venture capital index increased by 2.4% in 3Q14 (4Q14 results have not been publicly released) which exceeded the Nasdaq increase of 1.9%. More generally, the VC index has now surpassed Nasdaq for the past year, as well as the 10-year time frame and beyond, but lags Nasdaq in the 3 and 5-year time frames.

Nasdaq

Nasdaq increased 5.6% in 4Q14 and 13.8% for all of 2014, and has been flat in 1Q15 through February 4, 2015.

To read this Survey in full, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
17 Jan 2019, Workshop, California, United States

2018 brought a flurry of legislation and other developments in employment law that will undoubtedly affect your workplace.

20 Jan 2019, Conference, California, United States

Fenwick partner ​Kevin Kabler will be speaking at the IO Intellectual Property session (January 21 at 2pm).

20 Jan 2019, Conference, California, United States

Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions